Yogurt, probiotics and prebiotics linked to half the odds of colorectal cancer in older US adults
In a nationally representative US survey of adults 50+, yogurt, probiotic or prebiotic use was tied to about 50% lower odds of colorectal cancer history.
Summary
Using NHANES data from 2001–2020, researchers examined whether eating yogurt or taking probiotic or prebiotic supplements relates to colorectal cancer (CRC) among 9,405 US adults aged 50 and older, representing about 37 million people. About 1.5% reported a CRC history, 1.2% among consumers versus 2.1% among non-consumers. After adjusting for demographics, lifestyle, diet and health conditions, consumption was associated with roughly 50% lower odds of CRC (adjusted OR 0.50; 95% CI 0.29–0.88). Because the study is cross-sectional and relies on self-reported diagnoses, it cannot show that these products prevent cancer. The findings are hypothesis-generating and call for longitudinal studies.
Detailed Summary
Colorectal cancer is a leading cause of cancer illness and death worldwide, and diet is a modifiable risk factor. Red and processed meat raise risk, while fiber appears protective. Growing evidence points to the gut microbiota as a link between diet and CRC, since dysbiosis may drive inflammation and the production of carcinogenic metabolites. Probiotics, prebiotics and fermented foods such as yogurt could help keep the microbiota balanced, but national population-level data have been limited.
This study was a secondary analysis of the US National Health and Nutrition Examination Survey (NHANES) from 2001 to 2020. It included adults aged 50 and older, the age range for CRC screening, who answered the cancer-history questionnaire and had fasting glucose data. Of 97,657 initial participants, 9,405 were analyzed, representing about 37 million US residents after weighting. Participants reporting cancers other than CRC were excluded. CRC status came from self-reported cancer history and cancer type. Yogurt intake came from the Food Frequency Questionnaire. Prebiotic and probiotic use was identified by text-mining supplement and prescription records for terms such as inulin, fructooligosaccharides, Lactobacillus, Bifidobacterium and Saccharomyces boulardii. Weighted multivariable logistic regression accounted for NHANES's complex survey design. Covariates included age, sex, race/ethnicity, income, education, smoking, BMI, total energy, red meat and fiber intake, cardiovascular disease, chronic kidney disease, fasting glucose and serum albumin.
Participants had a mean age of 62.8 years; 53.4% were female and 73.7% were non-Hispanic White. In all, 151 people (1.5%) reported CRC. The prevalence was lower among those consuming yogurt, prebiotics or probiotics than among non-consumers (1.2% vs 2.1%, p = 0.023). Consumers (n = 5,540) differed from non-consumers (n = 3,865) in several ways. They were more often non-Hispanic White, not poor, high-school educated and of normal BMI, and less often current smokers. They had less diabetes and chronic respiratory disease, and higher fiber and energy intake. After adjustment, consumption was associated with about 50% lower odds of CRC (adjusted OR 0.50; 95% CI 0.29–0.88).
The authors interpret this as a possible protective association, plausibly mediated by gut microbiota modulation, consistent with prior literature on diet and cancer prevention. However, the mechanism was not tested in this study. The consumers' healthier socioeconomic and lifestyle profile suggests that residual confounding is a concern despite adjustment.
Key caveats are the cross-sectional design and reliance on self-reported CRC history. Only prevalent cases are captured, so reverse causation and survivor effects cannot be excluded. The number of CRC cases is small, and exposure was grouped across three different product types, with no dose, strain or duration information in the text provided. The supplied full text ended partway through the baseline table, so the detailed regression models, subgroup analyses and authors' own limitations section were not available for review. Longitudinal studies or trials are needed before any recommendation.
Key Findings
- Among 9,405 US adults aged 50+ (about 37 million weighted), 1.5% reported a history of colorectal cancer.
- CRC prevalence was 1.2% in yogurt/prebiotic/probiotic consumers versus 2.1% in non-consumers (p = 0.023).
- After full adjustment, consumption was associated with about 50% lower CRC odds (aOR 0.50; 95% CI 0.29–0.88).
- Consumers were more often non-Hispanic White, not poor, better educated and less often current smokers, so confounding is possible.
- Cross-sectional design means the study shows association only and cannot establish that these foods or supplements prevent CRC.
Methodology
Cross-sectional secondary analysis of NHANES 2001–2020 in adults aged 50 and older (n = 9,405). Yogurt intake came from the Food Frequency Questionnaire, prebiotic/probiotic use from text-mining of supplement and prescription records, and CRC from self-reported diagnosis. Weighted multivariable logistic regression accounted for the complex survey design, with progressively adjusted models.
Study Limitations
The cross-sectional design and self-reported CRC history preclude causal inference and are open to recall bias, reverse causation and survivor bias. Only 151 CRC cases were identified, exposure was pooled across yogurt, prebiotics and probiotics without dose or strain detail, and consumers differed in socioeconomic and lifestyle factors, so residual confounding is likely. The full text provided was truncated, so detailed model results were not reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: